Vol 89, No 6 (2018)
Research paper
Published online: 2018-06-29
Role of lymphadenectomy in disease-free and overall survival on low risk endometrium cancer patients
Abstract
Objectives: Evaluation of the effect of lymphadenectomy in disease-free and overall survival on the low risk corpus cancer.
Material and methods: Between 1994 and 2012, a total of 257 patients with endometrioid type, grade 1 or 2, myometrial invasion < 1/2, no intraoperative evidence of macroscopic extrauterine spread was treated surgically. Pelvic lymphadenectomy was performed in 184 cases, and not performed in 73 cases.
Results: There was no difference between two groups about tumor sizes. Also lymphovascular space invasion and histologic grade of two groups were similar. Omission of LA did not worsen DFS and OS in early stage low risk corpus cancer.
Conclusions: Patients who have low risk corpus cancer, can be treated optimally with hysterectomy only.
Keywords: endometrial cancerlow risklymphadenectomy
References
- Kulhan M, Kulhan G, Nayki U, et al. Assessment of clinicopathological features, evaluation of treatment, and prognosis of clear cell and serous papillary endometrial carcinoma. Ginekol Pol. 2016; 87(8): 570–574.
- Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1): 7–30.
- Arem H, Irwin ML, Zhou Y, et al. Physical activity and endometrial cancer in a population-based case-control study. Cancer Causes Control. 2011; 22(2): 219–226.
- Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol. 1989; 96(8): 889–892.
- Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009; 105(2): 103–104.
- Fotopoulou C, Savvatis K, Kraetschell R, et al. Systematic pelvic and aortic lymphadenectomy in intermediate and high-risk endometrial cancer: lymph-node mapping and identification of predictive factors for lymph-node status. Eur J Obstet Gynecol Reprod Biol. 2010; 149(2): 199–203.
- Hidaka T, Nakashima A, Shima T, et al. Systemic lymphadenectomy cannot be recommended for low-risk corpus cancer. Obstet Gynecol Int. 2010; 2010: 490219.
- Cragun JM, Havrilesky LJ, Calingaert B, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005; 23(16): 3668–3675.
- Zhang H, Jia L, Zhang Q, et al. Therapeutic role of systematic retroperitoneal lymphadenectomy in endometrial cancer. Bull Cancer. 2012; 99(2): E10–E17.
- Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008; 100(23): 1707–1716.
- Kitchener H, Swart AMC, Qian Q, et al. ASTEC study group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009; 373(9658): 125–136.
- FIGO stages 1988 revision. Gynecol Oncol. 1989; 35: 125–126.
- Mariani A, Webb MJ, Keeney GL, et al. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000; 182(6): 1506–1519.
- Convery PA, Cantrell LA, Di Santo N, et al. Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma. Gynecol Oncol. 2011; 123(1): 65–70.
- Milam MR, Java J, Walker JL, et al. Gynecologic Oncology Group. Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol. 2012; 119(2 Pt 1): 286–292.
- Shah C, Johnson EB, Everett E, et al. Does size matter? Tumor size and morphology as predictors of nodal status and recurrence in endometrial cancer. Gynecol Oncol. 2005; 99(3): 564–570.
- Trimble EL, Kosary C, Park RC. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol. 1998; 71(3): 340–343.
- Schink JC, Rademaker AW, Miller DS, et al. Tumor size in endometrial cancer. Cancer. 1991; 67(11): 2791–2794, doi: 10.1002/1097-0142(19910601)67:11<2791::aid-cncr2820671113>3.0.co;2-s.
- Kamura T, Yahata H, Shigematsu T, et al. Predicting pelvic lymph node metastasis in endometrial carcinoma. Gynecol Oncol. 1999; 72(3): 387–391.
- Mariani A, Dowdy SC, Keeney GL, et al. High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol. 2004; 95(1): 120–126.
- Mariani A, Dowdy SC, Cliby WA, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008; 109(1): 11–18.
- Kang S, Todo Y, Watari H. Risk assessment of lymph node metastasis before surgery in endometrial cancer: do we need a clinical trial for low-risk patients? J Obstet Gynaecol Res. 2014; 40(2): 322–326.
- Kang S, Kang WD, Chung HH, et al. Preoperative identification of a low-risk group for lymph node metastasis in endometrial cancer: a Korean gynecologic oncology group study. J Clin Oncol. 2012; 30(12): 1329–1334.
